OCT 06, 2016 06:00 AM PDT
Heterogeneity and Resistance Mechanisms in Advanced Prostate Cancer
Presented at the Cancer Research & Oncology Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
2 8 116

Speakers:
  • Director of Clinical Research of Urology Associates (UA)
    Biography
      Raoul S. Concepcion, M.D., F.A.C.S., is the current Director of Clinical Research of Urology Associates (UA), a fully integrated 32 physician Urology group in Nashville Tennessee. He is Immediate Past President of the Large Urology Group Practice Association (LUGPA), a non for profit entity representing the interests of over 2500 Urologists in the U.S. affiliated with large single specialty Urology groups. Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984 - 1989. He served as Chief Urology Resident from 1989 - 1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice with Urology Associates since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction. He has an academic appointment at The Vanderbilt School of Medicine as Associate Clinical Professor, Department of Urology. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeon and the Nashville Surgical Society. He also serves as a board member for ZERO, a non for profit organization for prostate cancer research based in Washington D.C., and the Nashville chapter of Gilda's Club. Dr. Concepcion serves as a speaker or consultant for many pharmaceutical and laboratory companies in the advanced prostate cancer and biomarker world, including Amgen, Dendreon, Janssen, Medivation, Astellas, Bayer, Algeta, Takeda, Mitomics, Myriad, Metamark Genetics and MDxHealth. He is also the co-founder of CUSP, a urology specific clinical trials organization, and Medical Advisor to the Chan Soon-Shiong Institute for Advanced Health and NantHealth.

    Abstract:
    Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castration resistant prostate cancer (mCRPC).  Despite these advances, however, the disease remains fatal and is the second leading cause of cancer specific death in men over the age of 50 years old in the United States.  This presentation will focus on the heterogeneity of prostate cancer, review the role of the androgen receptor (AR) in disease progression and discuss molecular mechanisms and mutations that result in treatment resistance.
     

    Show Resources
    Loading Comments...